2008 A Workshop on Issues in Clinical Prostate Cancer: Role of Imaging, June 23-25

From NCIGT Wiki
Jump to: navigation, search
Home < 2008 A Workshop on Issues in Clinical Prostate Cancer: Role of Imaging, June 23-25

The workshop will open with an evening plenary session in which speakers will present an overview of prostate cancer. During the next two days, participants will have the opportunity to discuss the following topics:


   * Diagnostic Accuracy (Reducing False-Positive and False-Negative Biopsies)
   * Risk Stratification/Initial Staging/Active Surveillance/Focal Therapy
   * D0 Disease (Prostate-Specific Antigen Relapse after Radiation Therapy or Radical Prostatectomy, Role of Imaging in Disease Management)
   * Assessing Response to Therapy: Role of Imaging in Prostate Cancer Drug Development and Management of Advanced Disease

Plenary sessions will be held for each of these four clinical topics followed by breakout group sessions and then round table discussions by opinion leaders. Your suggestions for topics to be addressed at the breakout and round table sessions are welcome.

Ms. Monica Barnette from Palladian Partners, Inc. is handling the registration and site logistics for this meeting.

please take a moment to complete your online registration to ensure that our meeting roster is complete and that your lodging requirements are met. Should you have any questions, please contact Ms. Barnette at: mbarnette@palladianpartners.com. Additionally, be sure to contact Omega World Travel to book your air or rail reservations.


Issues in Clinical Prostate Cancer: Role of Imaging

AGENDA

June 23–25, 2008

Goals of the Workshop: To define key areas where imaging research and development can improve prostate cancer management or enhance prostate cancer research and drug development; to define a pathway for the National Cancer Institute, Cancer Imaging Program to participate and assist in development of imaging research in prostate cancer.

Monday, June 23, EVENING PLENARY SESSION 6:00–6:30 pm Prostate Cancer Donald S. Coffey, PhD, Johns Hopkins Hospital

6:30–7:00 pm Clinical Prostate Cancer (General Overview––Incidence, Prevalence/Cancer Burden, Clinical Presentation, Clinical Course, Standard of Care/Patient Management) Howard I. Scher, MD, Memorial Sloan-Kettering Cancer Center

7:00–7:30 pm 	Prostate Cancer Pathology 
               Thomas M. Wheeler, MD, Baylor College of Medicine

7:30-8:30 pm Dinner

8:30–9:00 pm The Biology of Prostate Cancer

               David B. Agus, MD, University of California, Los Angeles, Geffen School of Medicine

9:00–9:30 pm Imaging and the Cancer Problem James Tatum, MD, National Cancer Institute, Cancer Imaging Program

9:30–10:00 pm Socio-Political Perspective on the Landscape of Prostate Cancer Imaging Research and its Support from Department of Defense, Health and Human Services, Prostate Cancer Foundation, Faster Cures, and Other Organizations Howard R. Soule, PhD, Executive Vice President, Discovery and Translation, Prostate Cancer Foundation

Tuesday, June 24, DAY 1

8:00–8:15 am Scope and Objectives of the Meeting

                Gary J. Kelloff, MD, National Cancer Institute, Cancer Imaging Program

Issue #1 Diagnostic Accuracy (Reducing False-Positive and False-Negative Biopsies)

8:15–8:30 am Early Disease Overview and Patient Management—What Is the Role of Imaging Today? What Clinical Needs are Best Met by Advances in Imaging? Peter Scardino, MD, Memorial Sloan-Kettering Cancer Center

8:30–8:45 am Prostate Pathology and Mapping

               M. Scott Lucia, MD, University of Colorado Health Science Center

8:45–9:00 am Imaging in Early Detection/Image Correlation with Prostate Pathology

               Peter Choyke. MD, National Cancer Institute Molecular Imaging Program

9:00–9:15 am PSA Screening and Markers for Early Detection

               William Catalona, MD, Northwestern University Feinberg School of Medicine

9:15–9:30 am Early Prostate Cancer Antigen (EPCA) Robert H. Getzenberg, MD, Johns Hopkins School of Medicine

Issue #2 Risk Stratification/Initial Staging/Active Surveillance/Focal Therapy

9:30–9:45 Prognostic Markers (What Improvements in Biomarkers or Imaging Would Lead to Better Prognosis/Risk Stratification?)

               Michael W. Kattan, PhD, Cleveland Clinic

9:45–10:00 am Imaging in Initial Staging of Prostate Cancer

               Mitchell D. Schnall, MD, PhD, University of Pennsylvania Medical Center

10:00–10:30 am Issues/Data in Active Surveillance

               Judd W. Moul, MD, FACS, Duke Prostate Center

10:15–10:30 am Issues/Data in Focal Therapy

               Michael Marberger, MD, Medical University of Vienna

10:30–10:45 am Coffee Break

10:45 am–12:30 pm Breakout Group for Issue #1 Discussion leaders (TBD) Speakers make brief 4–5 slide presentations of concepts/data with question-and-answer discussion, followed by an hour (or more) of leader-guided group discussions resulting in a report.

Ultrasound Ethan J. Halpern, MD, Thomas Jefferson Medical College

Magnetic Resonance (MR) Spectroscopy John Kurhanewicz, PhD, University of California, San Francisco

Ultrasound and MR Spectroscopy Ernest Feleppa, PhD, Riverside Research Institute

Raman Spectroscopy Jeffrey K. Cohen, MD, Triangle Urology Group

Diffusion-Weighted MR Imaging and 3D Spectroscopic Imaging—Correlation with Pathology Jason Koutcher, MD, PhD, Memorial Sloan-Kettering Cancer Center

10:45 am–12:30 pm Breakout Group for Issue #2 Discussion leaders (TBD) Speakers make brief 4–5 slide presentations of concepts/data with question-and-answer discussion, followed by an hour (or more) of leader-guided group discussions resulting in a report.

Staging (The Role of Imaging) Mukesh Harisinghani, MD, Harvard Medical School

Robotics, MRI Guided Diagnosis and Therapy, Target Volume Localization Clare Tempany, MB, Harvard Medical School

Image-Guided Brachytherapy (How is Imaging Used? What is Optimal?) Rodney J. Ellis, MD, Aultman Hospital

Cryoablation Aaron Katz, MD, Columbia University

Ultrasound-Guided Radio Frequency Ablation (What Are the Missing Pieces?) Michael Marberger, MD, Medical University of Vienna

High-intensity Focused Ultrasound (HIFU) Michael O. Koch, MD, Indiana University

12:30–1:30 pm Lunch

1:30–3:15 pm Report from Breakout Group #1 and Round table Discussion and Recommendations

3:15–3:30 pm Coffee Break

3:30–5:15 pm Report from Breakout Group #2 and Round table Discussion and Recommendations

6:00–7:00 pm Dinner

Issue # 3 D0 Disease (Prostate-Specific Antigen (PSA) Relapse after Radiation Therapy or Radical Prostatectomy, Role of Imaging in Disease Management)

7:00–7:15 pm Treatment Failure Post-Prostatectomy Peter Scardino, MD, Memorial Sloan-Kettering Cancer Center

7:15–7:30 pm Overview of Nonsurgical Treatment of Localized Prostate Cancer

 	        Intensity Modulated Radiation Therapy (IMRT) (Where are the Gaps in Knowledge?)
               Adam P. Dicker, MD, PhD, Thomas Jefferson University Hospital

7:30–7:45 pm Managing Node-Positive Disease, Role of Imaging, Improvements Needed

               Joycelyn Speight, MD, PhD, University of California, San Francisco

7:45–8:00 pm FDG-PET, role in Do Disease

               Richard L. Wahl, MD, Johns Hopkins University

Issue # 4 Assessing Response to Therapy/ Role of Imaging in Prostate Cancer Drug Development and Management of Advanced Disease

8:00–8:15 pm Advanced Disease Overview (Molecular Targets, Clinical Manifestations, Pathophysiology and Mechanism of Bone Metastases and Patient Management)

               Mario A. Eisenberger, MD, The Johns Hopkins University 


8:15–8:30 pm Molecular Imaging Probes of Potential Use in Prostate Cancer

               Martin G. Pomper, MD, PhD, The Johns Hopkins University School of Medicine 

8:30–8:45 pm Radionuclide Bone Scanning vs. 18Fluoro-2-Deoxyglucose-Positron Emission Tomography (FDG-PET)

               Steven M. Larson, MD, Memorial Sloan-Kettering Cancer Center

Wednesday, June 25, DAY 2

8:00-8:25 am Prostate Drugs Under Development in Industry: Are There Drugs That Can Be Imaged? Do Other Imaging-Detectable Biomarkers Exist for These Drugs?

               William L. Dahut, MD, National Cancer Institute

8:25-8:45 am Active/Completed Protocols in the Cooperative Groups

       	Maha Hussain, MD, University of Michigan

8:45–10:45 am Breakout Group for Issue # 3: Discussion leaders (TBD) Speakers make brief 4–5 slide presentations of concepts/data with question and answer discussion, followed by an hour (or more) of leader-guided group discussions resulting in a report.

Overview of PSA Kinetics Post-Therapy Howard Sandler, MD, Thomas Jefferson University Hospital

C-11 Choline, Acetate, Tyrosine, Methionine Karen A. Kurdziel, MD, National Cancer Institute, Molecular Imaging Program, and Gregory Ravizzini, MD, NIH, National Cancer Institute

Anti (18) F- FACBC David M. Schuster, MD, Emory University School of Medicine

MRI (or CT) Peter Choyke. MD, National Cancer Institute Molecular Imaging Program

FDG-PET and other PET Probes Richard L. Wahl, MD, Johns Hopkins University

8:45–10:45 am Breakout Group for Issue #4 Discussion leaders (TBD) Speakers make brief 4–5 slide presentations of concepts/data with question and answer discussion, followed by an hour (or more) of leader-guided group discussions resulting in a report.

Prevention of Bone Metastastases in Prostate Cancer Matthew R. Smith, MD, PhD, Massachusetts General Hospital Cancer Center

Radionuclide Bone Scanning vs. NaF PET Mukesh Harisinghani, MD, Harvard Medical School

Diffusion Imaging Mapping Maha Hussain, MD. University of Michigan

CT Mitchell D. Schnall, MD, PhD, University of Pennsylvania Medical Center

MRI in Late Stage Prostate Cancer Anwar Padhani, MB, FRCP, FRCR, Mount Vernon Cancer Centre

Imaging-Guided Drug Delivery Victor Frenkel, PhD, National Institutes of Health, Diagnostic Radiology Department, Clinical Center

10:45–11:00 am Coffee Break

11:00 am–12:45 pm Report from Breakout Group #3 and Round table Discussion and Recommendations

12:45–1:45 pm Lunch

1:45–3:45 pm Report from Breakout Group #4 and Round table Discussion and Recommendations

3:45–4:00 pm Wrap Up

4:00 pm Adjourn